Paschalis Evangelidis: A New Way to Treat iTTP by Targeting the Autoimmune Process
Paschalis Evangelidis, Former Teaching Assistant at Aristotle University of Thessaloniki (AUTH) shared a post on LinkedIn about a recent article he and Eleni Gavriilaki co-authored, adding:
”Excited to share our insightful commentary on immune-mediated thrombotic thrombocytopenic purpura (iTTP):
This piece highlights a promising shift in how we think about iTTP – not just managing acute episodes, but targeting the underlying autoimmune process.
A novel approach using red blood cells to deliver ADAMTS13 antigens in an ‘immune-silent’ way could help induce immune tolerance and reduce relapses.
While still early, this strategy opens the door to more precise, long-term solutions beyond conventional immunosuppression.
A small but meaningful step toward solving another piece of the TTP puzzle.”
Title: Solving another piece of the thrombotic thrombocytopenic purpura puzzle?
Authors: Paschalis Evangelidis, Eleni Gavriilaki
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 20, 2026, 16:51Suzan Nakasendwa: A Growing Stroke Challenge in Uganda
-
Oct 20, 2026, 16:38Steve Moon: How Does Smoking Cessation Duration Affect Ischemic Stroke Risk
-
Oct 20, 2026, 16:25Cedrice Mentor: Reducing Platelet Wastage Through Cold Storage
-
Oct 20, 2026, 16:09Thirunavukkarasu Angappan: Can a Purified Fibrinogen Concentrate Replace Cryoprecipitate
-
Oct 20, 2026, 16:01Kalyan Roy: Platelet Conservation Through Evidence-Based Transfusion Practice
-
Oct 20, 2026, 15:28Stacy E. Croteau: 33 Countries, One Mission – Better Bleeding Disorder Care
-
Oct 20, 2026, 15:19Teresa Barnes: What Does a Pulmonary Embolism Mean for Jalen Hurts?
-
Oct 20, 2026, 15:04Laura S.: Could Speaking Up Prevent Maternal Deaths from Thrombosis?
-
Oct 20, 2026, 14:44Pete Stibbs: VTE in Professional Athletes – When Fitness Is Not Enough